Clinical trial
Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid…
NCT00446342 · Sunesis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00446342 |
|---|---|
| Title | Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies |
| Official title | Phase 1 Multicenter, Dose-Escalation Clinical Study of the Safety and Tolerability of Intravenously Administered SNS-032 Injection, a Novel Cyclin-Dependent Kinase Inhibitor, Administered to Patients With Advanced B-Lymphoid Malignancies |
| Lead sponsor | Sunesis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | B-lymphoid Malignancies, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Multiple Myeloma |
| Intervention type | Drug |
| Interventions | SNS-032 Injection |
| Enrollment | 21 |
| Start date | Feb 1, 2007 |
| Primary completion | Dec 1, 2008 |
| Completion | Mar 1, 2009 |
| First posted | Mar 12, 2007 |
| Last update posted | Apr 11, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: